GKOS
Glaukos Corporation
Price Chart
Latest Quote
$134.65
+3.46 (+2.64%)
Current Price
| Previous Close | $131.19 |
| Open | $131.69 |
| Day High | $135.18 |
| Day Low | $131.50 |
| Volume | 427,586 |
Stock Information
| Shares Outstanding | 58.73M |
| Total Debt | $105.87M |
| Cash Equivalents | $276.68M |
| Revenue | $551.35M |
| Net Income | $-189.33M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $7.91B |
| EPS (TTM) | $-3.30 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.73B |
| Sales | $551.35M |
| Income | $-189.33M |
| Book/sh | $11.50 |
| Cash/sh | $4.71 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 4.43 |
| Current Ratio | 5.43 |
| Debt/Eq | 15.78 |
Returns & Margins
| ROA | -5.78% |
| ROE | -26.39% |
| Gross Margin | 78.08% |
| Operating Margin | -13.19% |
| Profit Margin | -34.34% |
Ownership
| Insider Ownership | 3.63% |
| Institutional Ownership | 101.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 303.52 |
| P/S | 14.34 |
| P/B | 11.71 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $157.50 |
Technical Indicators
| SMA20 | $120.62 |
| SMA50 | $126.51 |
| SMA200 | $108.21 |
| RSI | 77.68 |
| ATR | 5.7674 |
| Shares Float | 57.71M |
| Short Float | 6.44% |
| Short Ratio | 2.63 |
| Volatility | 0.81 |
| Rel Volume | 0.35 |
Performance History
| Week | +3.47% |
| Month | -3.15% |
| Quarter | +26.03% |
| 6 Months | +18.94% |
| YTD | +21.61% |
| Year | +34.45% |
| 3 Years | +99.51% |
| 5 Years | +68.27% |
| 10 Years | +377.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $134.65 | 427,586 |
| 2026-06-22 | $131.19 | 806,500 |
| 2026-06-18 | $130.68 | 984,200 |
| 2026-06-17 | $127.41 | 1,040,700 |
| 2026-06-16 | $127.53 | 724,500 |
| 2026-06-15 | $130.14 | 802,000 |
| 2026-06-12 | $126.81 | 708,000 |
| 2026-06-11 | $124.26 | 629,400 |
| 2026-06-10 | $122.49 | 1,542,200 |
| 2026-06-09 | $126.34 | 1,082,300 |
| 2026-06-08 | $121.96 | 962,100 |
| 2026-06-05 | $125.00 | 1,444,700 |
| 2026-06-04 | $121.69 | 1,584,200 |
| 2026-06-03 | $113.64 | 1,095,200 |
| 2026-06-02 | $110.78 | 1,867,000 |
| 2026-06-01 | $103.12 | 1,431,300 |
| 2026-05-29 | $103.35 | 1,708,700 |
| 2026-05-28 | $106.52 | 1,563,800 |
| 2026-05-27 | $109.88 | 1,231,500 |
| 2026-05-26 | $114.97 | 2,705,700 |
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
đ° Latest News
A Look At Glaukos (GKOS) Valuation After Recent Share Price Swings
Simply Wall St. âĸ 2026-06-09T13:11:12Z
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Zacks âĸ 2026-06-05T18:11:00Z
Medical Device Stocks Are Ready to Bounce. Two Names to Buy Now.
Barrons.com âĸ 2026-05-13T18:52:00Z
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations
Simply Wall St. âĸ 2026-05-04T02:13:40Z
Two Medical Stocks Skyrocket After Demolishing Views â And One Is About To Break Out
Investor's Business Daily âĸ 2026-04-30T20:06:26Z
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
Zacks âĸ 2026-04-30T14:53:00Z
Glaukos Q1 Earnings Call Highlights
MarketBeat âĸ 2026-04-30T08:05:31Z
Glaukos Corp (GKOS) Q1 2026 Earnings Call Highlights: Record Sales Surge and Raised Guidance
GuruFocus.com âĸ 2026-04-30T07:17:16ZGlaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks âĸ 2026-04-30T01:00:02Z
Glaukos Corporation Q1 2026 Earnings Call Summary
Moby âĸ 2026-04-30T00:26:21Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $224,681,000 | $94,027,000 | $75,575,000 | $68,979,000 |
| Cost Of Revenue | $224,681,000 | $94,027,000 | $75,575,000 | $68,979,000 |
| Total Revenue | $507,442,000 | $383,481,000 | $314,711,000 | $282,862,000 |
| Operating Revenue | $507,442,000 | $383,481,000 | $314,711,000 | $282,862,000 |
| Expenses | ||||
| Interest Expense | $4,635,000 | $10,040,000 | $13,633,000 | $13,720,000 |
| Total Expenses | $707,042,000 | $491,618,000 | $438,411,000 | $385,175,000 |
| Other Income Expense | $479,000 | $-38,529,000 | $-5,558,000 | $15,229,000 |
| Other Non Operating Income Expenses | $479,000 | $-24,300,000 | $-558,000 | $-4,771,000 |
| Net Non Operating Interest Income Expense | $6,079,000 | $1,065,000 | $-4,469,000 | $-11,345,000 |
| Interest Expense Non Operating | $4,635,000 | $10,040,000 | $13,633,000 | $13,720,000 |
| Operating Expense | $482,361,000 | $397,591,000 | $362,836,000 | $316,196,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-187,691,000 | $-146,372,000 | $-134,661,000 | $-99,195,000 |
| Net Interest Income | $6,079,000 | $1,065,000 | $-4,469,000 | $-11,345,000 |
| Interest Income | $10,714,000 | $11,105,000 | $9,164,000 | $2,375,000 |
| Normalized Income | $-187,691,000 | $-135,131,090 | $-130,711,000 | $-114,995,000 |
| Net Income From Continuing And Discontinued Operation | $-187,691,000 | $-146,372,000 | $-134,661,000 | $-99,195,000 |
| Total Operating Income As Reported | $-199,600,000 | $-122,366,000 | $-128,700,000 | $-82,313,000 |
| Net Income Common Stockholders | $-187,691,000 | $-146,372,000 | $-134,661,000 | $-99,195,000 |
| Net Income | $-187,691,000 | $-146,372,000 | $-134,661,000 | $-99,195,000 |
| Net Income Including Noncontrolling Interests | $-187,691,000 | $-146,372,000 | $-134,661,000 | $-99,195,000 |
| Net Income Continuous Operations | $-187,691,000 | $-146,372,000 | $-134,661,000 | $-99,195,000 |
| Pretax Income | $-193,042,000 | $-145,601,000 | $-133,727,000 | $-98,429,000 |
| Special Income Charges | $0 | $-14,229,000 | $-5,000,000 | $20,000,000 |
| Interest Income Non Operating | $10,714,000 | $11,105,000 | $9,164,000 | $2,375,000 |
| Operating Income | $-199,600,000 | $-108,137,000 | $-123,700,000 | $-102,313,000 |
| Gross Profit | $282,761,000 | $289,454,000 | $239,136,000 | $213,883,000 |
| Per Share | ||||
| Diluted EPS | $-3.28 | $-2.77 | $-2.78 | $-2.09 |
| Basic EPS | $-3.28 | $-2.77 | $-2.78 | $-2.09 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-2,988,090 | $-1,050,000 | $4,200,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-146,062,000 | $-81,410,000 | $-77,116,000 | $-68,763,000 |
| Total Unusual Items | $0 | $-14,229,000 | $-5,000,000 | $20,000,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-14,229,000 | $-5,000,000 | $20,000,000 |
| Reconciled Depreciation | $42,345,000 | $39,922,000 | $37,978,000 | $35,946,000 |
| EBITDA (Bullshit earnings) | $-146,062,000 | $-95,639,000 | $-82,116,000 | $-48,763,000 |
| EBIT | $-188,407,000 | $-135,561,000 | $-120,094,000 | $-84,709,000 |
| Diluted Average Shares | $57,190,000 | $52,755,000 | $48,433,000 | $47,444,000 |
| Basic Average Shares | $57,190,000 | $52,755,000 | $48,433,000 | $47,444,000 |
| Diluted NI Availto Com Stockholders | $-187,691,000 | $-146,372,000 | $-134,661,000 | $-99,195,000 |
| Tax Provision | $-5,351,000 | $771,000 | $934,000 | $766,000 |
| Research And Development | $150,614,000 | $136,425,000 | $138,768,000 | $123,271,000 |
| Selling General And Administration | $331,747,000 | $261,166,000 | $224,068,000 | $192,925,000 |
| Other Special Charges | - | $14,229,000 | $5,000,000 | $-20,000,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $447,529,000 | $437,352,000 | $112,676,000 | $156,002,000 |
| Total Assets | $893,487,000 | $974,756,000 | $940,414,000 | $1,002,383,000 |
| Total Non Current Assets | $418,503,000 | $524,964,000 | $544,953,000 | $558,524,000 |
| Other Non Current Assets | $25,693,000 | $25,448,000 | $21,325,000 | $17,691,000 |
| Goodwill And Other Intangible Assets | $208,626,000 | $329,579,000 | $349,090,000 | $374,003,000 |
| Other Intangible Assets | $141,916,000 | $263,445,000 | $282,956,000 | $307,869,000 |
| Current Assets | $474,984,000 | $449,792,000 | $395,461,000 | $443,859,000 |
| Other Current Assets | $24,052,000 | $12,455,000 | $18,194,000 | $17,250,000 |
| Inventory | $63,564,000 | $57,678,000 | $41,986,000 | $37,841,000 |
| Receivables | $108,608,000 | $60,744,000 | $39,850,000 | $36,073,000 |
| Accounts Receivable | $108,608,000 | $60,744,000 | $39,850,000 | $36,073,000 |
| Allowance For Doubtful Accounts Receivable | $-8,360,000 | $-1,073,000 | $-1,201,000 | $-1,250,000 |
| Gross Accounts Receivable | $116,968,000 | $61,817,000 | $41,051,000 | $37,323,000 |
| Cash Cash Equivalents And Short Term Investments | $278,760,000 | $318,915,000 | $295,431,000 | $352,695,000 |
| Cash And Cash Equivalents | $90,813,000 | $169,626,000 | $93,467,000 | $119,525,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $103,876,000 | $103,399,000 | $383,738,000 | $382,477,000 |
| Long Term Debt And Capital Lease Obligation | $103,876,000 | $103,399,000 | $383,738,000 | $382,477,000 |
| Net Debt | - | - | $189,306,000 | $161,875,000 |
| Long Term Debt | - | - | $282,773,000 | $281,400,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $237,332,000 | $207,825,000 | $478,648,000 | $472,378,000 |
| Total Non Current Liabilities Net Minority Interest | $136,057,000 | $132,700,000 | $404,634,000 | $400,019,000 |
| Other Non Current Liabilities | $31,740,000 | $22,373,000 | $13,752,000 | $10,278,000 |
| Non Current Deferred Liabilities | $441,000 | $6,928,000 | $7,144,000 | $7,264,000 |
| Non Current Deferred Taxes Liabilities | $441,000 | $6,928,000 | $7,144,000 | $7,264,000 |
| Current Liabilities | $101,275,000 | $75,125,000 | $74,014,000 | $72,359,000 |
| Payables And Accrued Expenses | $73,142,000 | $50,258,000 | $53,426,000 | $55,140,000 |
| Payables | $27,715,000 | $14,462,000 | $13,440,000 | $14,403,000 |
| Total Tax Payable | $3,091,000 | $1,436,000 | - | - |
| Accounts Payable | $24,624,000 | $13,026,000 | $13,440,000 | $14,403,000 |
| Equity | ||||
| Common Stock Equity | $656,155,000 | $766,931,000 | $461,766,000 | $530,005,000 |
| Total Equity Gross Minority Interest | $656,155,000 | $766,931,000 | $461,766,000 | $530,005,000 |
| Stockholders Equity | $656,155,000 | $766,931,000 | $461,766,000 | $530,005,000 |
| Gains Losses Not Affecting Retained Earnings | $3,303,000 | $2,615,000 | $1,165,000 | $-2,975,000 |
| Other Equity Adjustments | $3,303,000 | $2,615,000 | $1,165,000 | $-2,975,000 |
| Retained Earnings | $-933,130,000 | $-745,439,000 | $-599,067,000 | $-464,406,000 |
| Other | ||||
| Treasury Shares Number | $28,000 | $28,000 | $28,000 | $28,000 |
| Ordinary Shares Number | $57,511,000 | $56,444,000 | $49,120,000 | $47,754,000 |
| Share Issued | $57,539,000 | $56,472,000 | $49,148,000 | $47,782,000 |
| Tangible Book Value | $447,529,000 | $437,352,000 | $112,676,000 | $156,002,000 |
| Invested Capital | $656,155,000 | $766,931,000 | $744,539,000 | $811,405,000 |
| Working Capital | $373,709,000 | $374,667,000 | $321,447,000 | $371,500,000 |
| Capital Lease Obligations | $103,876,000 | $103,399,000 | $100,965,000 | $101,077,000 |
| Total Capitalization | $656,155,000 | $766,931,000 | $744,539,000 | $811,405,000 |
| Treasury Stock | $132,000 | $132,000 | $132,000 | $132,000 |
| Additional Paid In Capital | $1,586,056,000 | $1,509,831,000 | $1,059,751,000 | $997,470,000 |
| Capital Stock | $58,000 | $56,000 | $49,000 | $48,000 |
| Common Stock | $58,000 | $56,000 | $49,000 | $48,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $103,876,000 | $103,399,000 | $100,965,000 | $101,077,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $28,133,000 | $24,867,000 | $20,588,000 | $17,219,000 |
| Current Accrued Expenses | $45,427,000 | $35,796,000 | $39,986,000 | $40,737,000 |
| Goodwill | $66,710,000 | $66,134,000 | $66,134,000 | $66,134,000 |
| Net PPE | $184,184,000 | $169,937,000 | $174,538,000 | $166,830,000 |
| Accumulated Depreciation | $-55,539,000 | $-44,574,000 | $-34,477,000 | $-27,224,000 |
| Gross PPE | $239,723,000 | $214,511,000 | $209,015,000 | $194,054,000 |
| Leases | $81,831,000 | $80,987,000 | $70,332,000 | $60,621,000 |
| Construction In Progress | $11,900,000 | $8,087,000 | $17,379,000 | $17,875,000 |
| Other Properties | $107,322,000 | $104,267,000 | $101,169,000 | $97,128,000 |
| Machinery Furniture Equipment | $14,800,000 | $13,228,000 | $12,193,000 | $10,488,000 |
| Buildings And Improvements | $6,674,000 | $874,000 | $874,000 | $874,000 |
| Land And Improvements | $17,196,000 | $7,068,000 | $7,068,000 | $7,068,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $23,039,000 | $23,667,000 | $16,699,000 | $13,742,000 |
| Work In Process | $15,137,000 | $14,663,000 | $12,870,000 | $10,495,000 |
| Raw Materials | $25,388,000 | $19,348,000 | $12,417,000 | $13,604,000 |
| Other Short Term Investments | $187,947,000 | $149,289,000 | $201,964,000 | $233,170,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-39,062,000 | $-67,618,000 | $-78,006,000 | $-63,348,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-14,789,000 | $-61,318,000 | $-57,758,000 | $-33,083,000 |
| Cash Flow From Continuing Operating Activities | $-14,789,000 | $-61,318,000 | $-57,758,000 | $-33,083,000 |
| Operating Gains Losses | $-1,184,000 | $5,218,000 | $-87,000 | $2,218,000 |
| Investing Activities | ||||
| Capital Expenditure | $-24,273,000 | $-6,300,000 | $-20,248,000 | $-30,265,000 |
| Investing Cash Flow | $-77,613,000 | $47,831,000 | $14,095,000 | $44,779,000 |
| Cash Flow From Continuing Investing Activities | $-77,613,000 | $47,831,000 | $14,095,000 | $44,779,000 |
| Net Other Investing Changes | $-5,550,000 | $-3,151,000 | $-3,170,000 | - |
| Financing Activities | ||||
| Financing Cash Flow | $11,886,000 | $91,540,000 | $15,042,000 | $6,251,000 |
| Cash Flow From Continuing Financing Activities | $11,886,000 | $91,540,000 | $15,042,000 | $6,251,000 |
| Net Other Financing Charges | $-8,132,000 | $46,366,000 | $-3,273,000 | $-2,429,000 |
| Other | ||||
| Repayment Of Debt | $-1,121,000 | $-1,589,000 | $-711,000 | $-527,000 |
| Interest Paid Supplemental Data | $4,212,000 | $9,210,000 | $12,254,000 | $12,340,000 |
| Income Tax Paid Supplemental Data | $949,000 | $1,360,000 | $1,557,000 | $522,000 |
| End Cash Position | $94,647,000 | $174,359,000 | $99,323,000 | $126,603,000 |
| Beginning Cash Position | $174,359,000 | $99,323,000 | $126,603,000 | $110,124,000 |
| Effect Of Exchange Rate Changes | $804,000 | $-3,017,000 | $1,341,000 | $-1,468,000 |
| Changes In Cash | $-80,516,000 | $78,053,000 | $-28,621,000 | $17,947,000 |
| Proceeds From Stock Option Exercised | $21,139,000 | $46,763,000 | $19,026,000 | $9,207,000 |
| Net Issuance Payments Of Debt | $-1,121,000 | $-1,589,000 | $-711,000 | $-527,000 |
| Net Long Term Debt Issuance | $-1,121,000 | $-1,589,000 | $-711,000 | $-527,000 |
| Long Term Debt Payments | $-1,121,000 | $-1,589,000 | $-711,000 | $-527,000 |
| Net Investment Purchase And Sale | $-35,353,000 | $57,244,000 | $37,513,000 | $74,893,000 |
| Sale Of Investment | $196,938,000 | $247,199,000 | $303,100,000 | $135,157,000 |
| Purchase Of Investment | $-232,291,000 | $-189,955,000 | $-265,587,000 | $-60,264,000 |
| Net Business Purchase And Sale | $-12,437,000 | $0 | $0 | - |
| Purchase Of Business | $-12,437,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-24,273,000 | $-6,262,000 | $-20,248,000 | $-30,114,000 |
| Sale Of PPE | $0 | $38,000 | $0 | $151,000 |
| Purchase Of PPE | $-24,273,000 | $-6,300,000 | $-20,248,000 | $-30,265,000 |
| Change In Working Capital | $-48,021,000 | $-40,045,000 | $-10,494,000 | $-13,448,000 |
| Change In Payables And Accrued Expense | $18,824,000 | $21,000 | $1,305,000 | $7,210,000 |
| Change In Prepaid Assets | $-6,123,000 | $1,259,000 | $-2,765,000 | $-1,720,000 |
| Change In Inventory | $-7,702,000 | $-19,450,000 | $-5,360,000 | $-15,472,000 |
| Change In Receivables | $-53,020,000 | $-21,875,000 | $-3,674,000 | $-3,138,000 |
| Changes In Account Receivables | $-53,020,000 | $-21,875,000 | $-3,674,000 | $-3,138,000 |
| Other Non Cash Items | $1,782,000 | $28,993,000 | $7,422,000 | $2,158,000 |
| Stock Based Compensation | $63,218,000 | $50,207,000 | $43,528,000 | $38,561,000 |
| Provisionand Write Offof Assets | $8,718,000 | $571,000 | $361,000 | - |
| Asset Impairment Charge | $115,512,000 | $4,449,000 | $0 | $0 |
| Amortization Of Securities | $-2,981,000 | $-4,045,000 | $-1,685,000 | $731,000 |
| Deferred Tax | $-6,487,000 | $-216,000 | $-120,000 | $-54,000 |
| Deferred Income Tax | $-6,487,000 | $-216,000 | $-120,000 | $-54,000 |
| Depreciation Amortization Depletion | $42,345,000 | $39,922,000 | $37,978,000 | $35,946,000 |
| Depreciation And Amortization | $42,345,000 | $39,922,000 | $37,978,000 | $35,946,000 |
| Amortization Cash Flow | $27,128,000 | $24,701,000 | $24,912,000 | $24,912,000 |
| Amortization Of Intangibles | $27,128,000 | $24,701,000 | $24,912,000 | $24,912,000 |
| Depreciation | $15,217,000 | $15,221,000 | $13,066,000 | $11,034,000 |
| Net Foreign Currency Exchange Gain Loss | $-1,216,000 | $4,620,000 | $-980,000 | $2,242,000 |
| Gain Loss On Sale Of PPE | $32,000 | $598,000 | $893,000 | $-24,000 |
| Net Income From Continuing Operations | $-187,691,000 | $-146,372,000 | $-134,661,000 | $-99,195,000 |
| Change In Other Current Assets | - | $-2,075,000 | $-1,880,000 | $-328,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Sale Of Business | - | - | - | - |
Fetched: 2026-06-17